dm+d

Unassigned

New Medicines

EryDexAtaxia telangiectasia - first-line in adults and children

Information

EryDex
New formulation (point of care manufacture)
EryDel
EryDel

Development and Regulatory status

Phase III Clinical Trials
Phase III Clinical Trials
Phase III Clinical Trials
Yes
Yes

Category

A solution of dexamethasone sodium phosphate encapsulated into human erythrocytes.
Ataxia telangiectasia (AT) is an autosomal recessive, multi-system disorder resulting from defects in the AT mutated (ATM) gene and is characterised by severe progressive neurodegeneration, including cerebellar ataxia (upper and lower limbs), speech difficulties and abnormal eye movements. About 200 patients in the UK suffer from AT [2].
Ataxia telangiectasia - first-line in adults and children
Intravenous infusion

Evidence based evaluations